Ropinirole, a dopamine agonist with high D$_3$ affinity, reduces proactive inhibition: a double-blind, placebo-controlled study in healthy adults

Vishal Rawji, Lorenzo Rocchi, Tom Foltynie, John C. Rothwell and Marjan Jahanshahi

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, Queen Square, London, UK

Corresponding author email address: vishal.rawji.11@ucl.ac.uk

Abstract

Response inhibition describes the cognitive processes mediating the suppression of unwanted actions. A network involving the basal ganglia mediates two forms of response inhibition: reactive and proactive inhibition. Reactive inhibition serves to abruptly stop motor activity, whereas proactive inhibition is goal-orientated and results in slowing of motor activity in anticipation of stopping. Due to its impairment in several psychiatric disorders, the neurochemistry of response inhibition has become of recent interest. Dopamine has been posed as a candidate mediator of response inhibition due to its role in functioning of the basal ganglia and the observation that patients with Parkinson's disease on dopamine agonists develop impulse control disorders. Although the effects of dopamine on reactive inhibition have been studied, substantial literature on the role of dopamine on proactive inhibition is lacking. To fill this gap, we devised a double-blind, placebo-controlled study of 1 mg ropinirole (a dopamine agonist) on response inhibition in healthy volunteers. We found that whilst reactive inhibition was unchanged, proactive inhibition was impaired when participants were on ropinirole relative to when on placebo. To investigate how ropinirole mediated this effect on proactive inhibition, we used hierarchical drift-diffusion modelling. We found that ropinirole impaired the ability to raise the decision threshold when proactive inhibition was called upon. Our results provide novel evidence that an acute dose of ropinirole selectively reduces proactive inhibition in healthy participants. These results may help explain how ropinirole induces impulse control disorders in susceptible patients with Parkinson's disease.

Introduction

Response inhibition describes the cognitive processes involved in the suppression of unwanted thoughts and action [1]. It can be divided into reactive and proactive inhibition, whereby reactive inhibition is called upon in response to sudden sensory cues and serves to abruptly stop motor activity, whereas proactive inhibition is goal-orientated and results in slowing of motor activity in anticipation of stopping. A breakdown in response inhibition is a feature of several psychiatric disorders such as schizophrenia [2], addiction [3] and attention deficit hyperactivity disorder [4]. This has encouraged a drive to further understand the neurochemical substrates of response inhibition. Use of dopamine agonist medication in Parkinson's disease (PD) has been shown to predispose to impulse control disorders (ICDs), manifesting as pathological gambling, hypersexuality and excessive shopping [5]. This observation has therefore prompted investigation of dopamine as a mediator of response inhibition.

A network involving the basal ganglia, right inferior frontal gyrus and pre-supplementary motor area has been implicated in volitional and habitual inhibition [1], and in mediating stopping on behavioural tasks employed to probe reactive and proactive inhibition [6]. Since dopamine is a key neurotransmitter modulating activity in these regions, it seems plausible to study the role of dopamine in response inhibition [7,8]. Infusions of a selective D_1 receptor antagonist into the rat striatum improves reactive motor inhibition, whereas infusions of a D_2 receptor antagonist impairs it [9]. In humans, positron emission tomography of striatal D_2 and D_3 receptor availability is negatively correlated with the speed of response inhibition and positively correlated with inhibition related functional magnetic resonance imaging activation in the fronto-striatal stopping network [10]. Administration of the dopamine and noradrenaline reuptake inhibitor, amphetamine, increases D_2 receptor expression and improves measures of reactive inhibition [11].

In addition to the link between D_1/D_2 receptors, response inhibition and impulsivity [12], an association between dopamine agonists with D_3 receptor affinity and ICD generation in PD has been found; with pramipexole and ropinirole being two agents both with relatively high D_3 affinity compared to other dopamine agonists and greatest risk of ICD generation [13,14]. The link between use of dopamine agonists with relatively high D_3 affinity and response inhibition remains limited and only reactive inhibition has been explored [15,16]. The effect of these agents on proactive inhibition, on the other hand, has not been investigated.

Our aim was to investigate the effect of dopamine agonists on reactive and proactive response inhibition in healthy participants. We chose the dopamine agonist, ropinirole, which is commonly used clinically and has been implicated in the generation of ICDs in PD. Ropinirole directly activates dopamine receptors with a relatively high affinity for D_3 receptors [17,18] and hence is a suitable candidate to explore the effect of dopamine agonists on motor inhibition. We devised a randomised, double-blind, placebo-controlled trial to investigate reactive and proactive inhibition in a conditional stop signal task (CSST) under the influence of a placebo or ropinirole.

Methods

Participants

Participants were recruited from the staff and students of University College London. Participants were screened to exclude any psychiatric or neurological illness, drug or alcohol abuse and also for any contraindications to ropinirole. A power calculation showed that 30 participants would be needed to show a 20% reduction of the response delay effect (RDE), measure of proactive inhibition, under ropinirole, assuming an intraclass correlation coefficient of 0.655 with 80% power at an alpha level of 0.05. Therefore, 30 healthy volunteers (20 male) aged 19-30 (mean age 23.63, SD 3.64) participated in this study.

Conditional Stop-signal task (CSST)

The conditional stop-signal task (CSST) is a validated task to probe reactive and proactive inhibition [19–22]. Participants performed four blocks of the CSST driven by a custom-made MATLAB (MathWorks) script using Psychtoolbox. Each block consisted of 102 go trials (51 critical, 51 non-critical) and 34 stop trials (17 critical and 17 non-critical). A trial on the CSST begins with a white fixation cross, which is replaced 500 ms later by one of two imperative stimuli (right or left arrow). The presentation of these arrows is random, and each occurs with 50% probability. The participant is asked to respond as quickly as possible to the right or left imperative stimulus by pressing the 'M' or 'Z' key on the keyboard with their right or left index fingers, respectively. On 25% of the trials, a stop signal is presented after the go signal, which instructs participants to abort their ongoing movement (stop trial). The timing of this delay between go and stop signals is called the stop signal delay (SSD). The SSD can occur at one of four time points (100, 150, 200 and 250 ms) and was adjusted using a staircase tracking procedure. The SSD for a particular trial was altered based on the

outcome of the previous trial; successfully stopping in the previous stop trial would increase SSD by 50 ms (to make the next trial harder to inhibit). Failure to stop on a stop trial would decrease SSD by 50 ms in the next trial (thereby making stopping easier on the next trial). SSD was set to 150 ms at the beginning of each block. Catch trials, where no signals were given, were also presented. At the beginning of each block, participants were told that they would have to follow the stopping rule if the stop signal was presented for one direction (critical direction) but to ignore the stop signal if it appeared after the other imperative signal (non-critical direction). Hence, responses between the critical and non-critical responses could be compared to determine proactive control. The structure of the block was pseudorandomised, such that one stop trial appears in every four trials.


Figure 1: The Conditional stop-signal task (CSST).

The different trial types on the CSST with their appropriate responses (critical direction is right). All stimuli stay on the screen until the next stimulus appears. The stop signal delay (SSD) changes between one of four values depending on the performance of the previous critical stop trial.

Reaction times were measured as the time interval between the imperative stimulus (right arrow) onset and the button press. Trials were first organised into whether they were to the

critical or non-critical direction. For ease, the remainder of this section will refer to 'right' as the critical direction and left as the non-critical direction. The critical go reaction time was the reaction time measured on critical (right arrow) go trials and the non-critical go reaction time was the reaction time measured during non-critical (left arrow) go trials. p(inhibit) was calculated as the proportion of successful stop trials (where the participant correctly aborted their response) to the critical (right) direction. The reaction time on failed stop trials (stop trials where the participant failed to stop and hence pressed a button) was also calculated (Stop respond reaction time). The stop-signal reaction time (SSRT) was calculated using the integration method [23,24]. The number of omitted trials were also recorded – omitted trials were ones where no button press was made. Participants slow down their responses in anticipation of potential stopping – which reflects proactive inhibition. To measure this behaviourally, we calculated the response delay effect (RDE) by subtracting the non-critical (left) go reaction time from the critical (right) go reaction time. Conflict-induced slowing (CIS), a measure of temporary braking to stop signals on non-critical trials, was measured by subtracting the non-critical go reaction time (left go trial) from the non-critical stop reaction time (left stop trial). Importantly, participants were told to prioritise responding to go stimuli and not to slow-down in anticipation of a stop-signal.

Protocol

The study was approved by the Local Ethics Committee (UCL Ethics ID: 9669/002). Written, informed consent was obtained from each participant. After performing one block of the CSST, as a practice block, participants were then given one of two pills (ropinirole 1mg or placebo). Both the participants and the experimenter were blinded and only a third-party investigator, not part of the study, knew the identity of the pills. For each participant, the pill given was selected using a random number generator. The participant stayed in the room for one hour, a time period consistent for ropinirole to reach an appropriate blood level to have CNS effects [25,26]. Following this, the participants performed four blocks of the CSST: two blocks with right as the critical direction and two blocks with left at the critical direction. The order of these blocks was also randomised. After at least 48 hours, the participant returned to the laboratories and underwent the same protocol as session one, except with the other pill.

Drift-diffusion modelling

A Bayesian hierarchical drift-diffusion model (HDDM) [27] was used to investigate the strategic effects on task performance on the go trials of the CSST when stopping may

(critical) or may not (non-critical) be required. DDMs are used to model two-choice, decision-making tasks and aim to resolve the parameters modulated when decisions are made under different circumstances. The model outline is such that activity starts at a starting point (z). After a delay for sensory processing of the imperative stimulus (n_1), activity increases towards one of two decision boundaries (a, one for each choice) at a rate (v). When activity reaches one of the thresholds, the choice is selected; after another delay for motor execution (n_2), the choice is made. Usually, the delays for sensory processing and motor execution are combined into one non-decision time (n).

We used the HDDM to investigate how ropinirole modulated decision-making parameters during the CSST. Crucially, the HDDM results in better model fits by taking advantage of both the similarity and differences between the participants' performance; individual participant parameters are drawn from a group posterior such that if participants are similar, the variance in the group distribution is small. We used the HDDM toolbox [27] to estimate DDM parameters. We computed seven different models by varying drift rate, boundary separation and non-decision time between context (critical vs non-critical) and drug (ropinirole vs placebo). The starting point was set to half of the boundary separation since the left/right go cues could appear with equal probability. The optimal model was chosen by using the deviance information criterion (DIC), where a lower DIC indicates a higher likelihood for that model. To maximise available data for the model, we combined all four blocks per drug condition by labelling trials as critical and non-critical, independent of whether they were right or left-handed responses. Markov chain Monte Carlo sampling methods were used to construct the posteriors distribution for parameters (10,000 samples generated, 2000 burn in). To confirm model convergence, we calculated the R-hat (Gelman-Rubin) statistic.

Data analyses
We were particularly interested in how behavioural inhibition was altered under the influence of the dopamine agonist, ropinirole. To this end, we performed paired t-tests between conditions (ropinirole and placebo) for the following parameters: RDE (proactive inhibition), SSRT (reactive inhibition), CIS, and go discrimination errors. We considered p values of < 0.05 as statistically significant.

Using the HDDM allowed for Bayesian analysis of posterior probability distributions for each parameter, between drug (ropinirole vs placebo) and trial type (critical vs non-critical) conditions. Posterior probabilities of greater than 95% were considered significant.

Results

Behavioural measures

Behavioural measurements are shown in Table 1. As expected from the race model, reaction times on failed stop trials (Stop respond) were faster than reaction times on critical go trials for both placebo and ropinirole conditions (placebo: $t = 9.20$, $p < 0.001$, $d = 0.74$, 95% CI [0.21 – 1.25]; ropinirole: $t = 3.78$, $p = 0.001$, $d = 0.39$, 95% CI [-0.13 – 0.89]). There was also an expected go reaction time difference between critical and non-critical trials measured as RDE due to the anticipation of stopping on critical trials (placebo: $t = 11.00$, $p < 0.001$, $d = 0.99$, 95% CI [0.44 – 1.51]; ropinirole: $t = 3.78$, $p = 0.001$, $d = 0.87$, 95% CI [0.33 – 1.39]).

Measure	Measure description	Drug	
		Placebo	**Ropinirole**
Critical Go	RT to go stimulus in the critical direction	456.94 (73.97)	460.53 (76.30)
p(inhibit)	% correct inhibition	58.08 (15.57)	53.92 (14.47)
Stop Respond	RT on failure to stop trials	406.00 (65.76)	428.65 (71.70)
Go error	% of go discrimination errors	0.60 (0.72)	1.06 (1.19)
Stop signal delay	Delay between go and stop signals	188.82 (33.32)	176.34 (32.25)
SSRT	Estimated time take to abort response	276.29 (83.68)	279.81 (75.65)
Non-critical Go	RT to go stimulus in the non-critical direction	386.62 (75.35)	402.00 (75.64)
Non-critical Stop	RT to stop stimulus in the non-critical	430.30	444.62

	direction	(111.48)	(108.96)
Response delay effect	(Critical go) - (Non-critical go) RT	70.32 (35.00)	58.53 (30.78)
Conflict-induced slowing	(Non-critical stop) – (Non-critical go) RT	44.81 (47.17)	48.23 (54.04)

Table 1: Behavioural measurements from the Conditional Stop-signal task performed by participants on placebo and ropinirole. Mean values are accompanied by SD in brackets. Reaction times are given in milliseconds.

Ropinirole reduces proactive inhibition and induces more commission errors

We performed a paired t-test between the RDE for placebo and ropinirole and found significantly reduced proactive inhibition on ropinirole (t = 2.25, p = 0.032, d = 0.36, 95% CI [-0.16 – 0.86]). The SSRT is a measure of reactive inhibition; it is the estimated time taken for stopping on presentation of the stop signal. A paired t-test comparing the SSRTs between drug conditions showed that reactive inhibition was unchanged on ropinirole relative to placebo (t = 0.29, p = 0.770, d = 0.04, 95% CI [-0.55 – 0.46]). We also found that under the influence of ropinirole, participants made more go discrimination errors than when on placebo (t = 2.29, p = 0.029, d = 0.47, 95% CI [-0.05 – 0.98]). CIS was unchanged on ropinirole compared to placebo (t = -0.41, p = 0.682, d = -0.07, 95% CI [-0.57 – 0.44]).

On ropinirole, reduced proactive inhibition is due to failure to raise the decision threshold in anticipation of stop trials

Of the seven models we tested, the one with the lowest DIC was a model allowing boundary separation, drift rate and non-decision time to vary (Table 2); parameter estimation therefore comes from this model. To validate the model, we simulated data for each trial type, under each drug condition, using the parameters from the model with the lowest DIC. The model recapitulated both the mean reaction times (critical go placebo: 461.67 ms, non-critical go placebo: 385.48 ms, critical go ropinirole: 468.41 ms, and non-critical go ropinirole: 400.57 ms) and reaction time distributions for each drug/trial permutation, shown in Figure 2. Figure 3 shows the posterior parameter estimation for the critical and non-critical Go trials in the

ropinirole and placebo conditions. We first looked at the effect of trial type: during critical Go trials, when participants were slowing their responses and hence employing proactive inhibition, boundary separation was greater (posterior probability 100%), drift rate was lower (posterior probability 100%) and non-decision time was shorter (posterior probability 99.96%), compared to non-critical Go trials. Turning our attention to the effect of ropinirole, we found that participants' boundary separation was smaller (posterior probability 100%), drift rate was lower (posterior probability 100%) and non-decision time was smaller (posterior probability 98.66%), compared to when assessed on placebo.

From the behavioural analysis, we saw that the RDE was smaller on ropinirole than on placebo; indicating that participants engaged in less proactive inhibition on ropinirole. To investigate how this could arise, we looked for interaction effects between drug and trial type for each DDM parameter. We found that ropinirole specifically impaired the ability to raise the decision threshold on trials when stopping might be required (posterior probability 98.60%). A significant interaction between drug and trial type was not present for drift rate (posterior probability 85.43%) or non-decision time (posterior probability 48.99%).

Model	DIC
a	-46135.48
v	-46842.23
t	-45503.35
a,v	-46795.34
a,n	-46178.97
v,n	-46741.94
a,v,n	-47170.71

Table 2: Deviance information criterion values for each model. The Table shows the DIC value for each model tested. A lower DIC value indicates a greater likelihood for that model. a = boundary separation, v = drift rate, n = non-decision time.

Figure 2: Real and HDDM-predicted reaction times.

Plots show predicted (red) and real (blue) reaction times organised by quantile, for each trial/drug permutation. Reaction times are simulated using the HDDM model with the lowest DIC value.

Figure 3: Drift-diffusion model parameters between critical and non-critical Go trials for participants on ropinirole or placebo.

Posterior probability distributions are plotted for drug (ropinirole), trial type (non-critical) and an interaction between the two. The blue, vertical line represents the no-effect value. Statistical significance is confirmed if >95% of the distribution lies outside of this line.

Discussion

A single dose of ropinirole reduces/impairs proactive inhibition in healthy participants

We present data showing how proactive and reactive inhibition are modulated after administration of a single dose of ropinirole, a dopamine agonist with relatively high D_3 affinity. The data show that proactive inhibition is reduced with administration of ropinirole, indexed by a significant decrease in the RDE. This was accompanied by an increase in the number of go discrimination errors on ropinirole relative to placebo. This is a rather surprising finding since the imperative stimuli are unambiguous, but consistent with a

previous report that dopamine replacement in PD resulted in more perceptual decision-making errors on a random motion dots task [28]. By contrast, reactive inhibition as measured by the SSRT, was unaffected by ropinirole administration.

Traditionally, observational and correlative studies have indicated a role of dopamine in response inhibition. Patients with PD (acting as a proxy for chronic dopamine deficiency) show impairments in a variety of tasks probing response inhibition [19], although proactive inhibition seems unaltered in untreated patients [20]. Functional neuroimaging studies show an inverse relationship between dopamine receptor (D_1 and D_2) availability and response inhibition [10,29–31]. Interventional studies have shown similar results, with dopaminergic antagonism using haloperidol, resulting in impaired reactive inhibition [32] and dopaminergic agonism using cabergoline or methylphenidate, resulting in improved reactive inhibition [33,34].

A role of ropinirole in response inhibition has been previously explored in healthy adults. In that study, participants were randomised to receive a placebo, 0.5 mg or 1 mg of ropinirole and asked to perform two tasks of response inhibition: a the stop signal task to measure reactive inhibition and a balloon analogue risk task, measuring decisional inhibition, which could be regarded as a form of proactive inhibition. Interestingly, this group also genotyped their participants to derive a dopamine genetic risk score (made up of *DRD1, DRD2, DRD3, DAT* and *COMT* polymorphisms), which indexed basal dopamine neurotransmission. They found that ropinirole modulated both forms of inhibition depending on individuals' genetic risk score and concluded, as have others [35,36], that dopamine follows an inverted-U shape dose-response relationship with regard to response inhibition [16]. Whilst we did not measure our participants' dopamine genetic risk score, our results on motor, rather than decisional inhibition reinforce the finding that dopamine agonists modulate proactive response inhibition. It may be the case the underlying genetic susceptibility determines the risk of impulsivity in PD. Indeed, the predictability of ICD generation in PD patients on dopamine replacement is increased when genes associated with ICDs are included in the prediction model [37].

Although the aforementioned studies have informed the role of dopamine in reactive inhibition, the literature concerning dopamine and proactive inhibition remains scarce. D_1 and D_2 gene polymorphisms have been shown to predict engagement of proactive inhibition (measured as post-error slowing in a go/no-go task), such that increased D_1 and decreased D_2 receptor expression are associated with increased proactive inhibition [38]. Given that

ropinirole has a relatively high affinity for D_3 receptors, our work extends the mediators of proactive inhibition to include D_3 receptors, as well.

Ropinirole resulted in less context-specific modulation of boundary separation

We investigated the strategy that participants employed when stopping might be required. Under both ropinirole and placebo, our participants decreased their non-decision time, reduced their drift rate and increased their boundary separation on trials when stopping might be required, the latter confirming previous literature [20]. We then asked what specific effects ropinirole administration had on changes in strategy when stopping might be required. We found that ropinirole resulted in less context-specific adjustment of the boundary separation when stopping was potentially required on critical trials. This finding was in keeping with the behavioural results, where a significantly smaller RDE and a greater number of commission errors were observed. Interestingly, our results mirror those found by Obeso et al. in patients with PD having undergone therapeutic unilateral subthalamotomy. They used the CSST to investigate proactive and reactive inhibition, and found impaired RDE coupled with a failure to engage in context-dependent adjustment of boundary separation during critical trials after right-sided subthalamotomy [20].

Modulation of the dopaminergic system has been shown to alter strategy used during decision-making. Beste and co-workers used methylphenidate, a dopamine/noradrenaline reuptake inhibitor, to study perceptual decision making in healthy individuals using the random motion dots task. They found that administration of methylphenidate significantly increased drift rates compared to placebo and showed that modulation of the dopaminergic system can selectively modulate evidence accumulation [39]. Polymorphisms in dopamine genes have been related to the strategy used during a selective stop signal task [40]. Hence, in addition to acting as a mediator of reactive inhibition, it seems that dopamine has a role in setting the proactive strategy used during specific tasks.

The speed-accuracy tradeoff is a feature of decision-making, whereby decisions that are made faster suffer from decreased accuracy, whereas those that are more accurate are generally slower. The mechanisms by which this tradeoff occurs have been explained using DDMs, with increases in boundary separation resulting in greater accuracy and slower reaction times [41]. Winkel et al. have investigated the role of a dopamine agonist, bromocriptine, on the speed-accuracy tradeoff using the random motion dots task. They failed to find an effect of

bromocriptine on boundary separation in mediating the tradeoff [42]. Crucially, the dopamine receptor affinity profile of bromocriptine differs from that of ropinirole; whilst both agents have a high affinity for D_2 receptors, ropinirole has a relatively higher affinity for D_3 receptors than bromocriptine. Also, the random motion dots task primarily alters decision-making via changes in drift rate via manipulation of motion coherence of the dots, whereas in the CSST, proactive inhibition is modulated by a combination of strategies. It may be the case that dopamine does indeed have the potential to mediate the speed-accuracy tradeoff via D_3 receptors. These studies and our own highlight that the role of dopamine in perceptual decision-making is complex, with interactions between neurotransmitter/receptor specificity and design of behavioural tasks.

Limitations

Although ropinirole has a relatively high affinity for D_3 receptors, we are aware that it acts on the family of D_2-like receptors, which include D_2, D_3 and D_4 receptors [43]. Therefore, we are unable to pinpoint the effects of ropinirole on proactive inhibition specifically on D_3 receptor activity. Whether our findings can be generalized to all dopamine agonists remains to be established; the effect observed in this study may be specific to ropinirole. Future studies could therefore aim to explore a number of dopamine agonists with varying D_3 receptor activity. If causative, then deficits in proactive inhibition should scale with dopamine agonist D_3 receptor affinity. Whilst we have drawn parallels between our findings and impulsivity in PD, we note two important caveats; our participants have a preserved dopaminergic state, whereas patients with PD have variable dopaminergic denervation in motor and limbic regions. Furthermore, the doses received by patients with PD typically exceed those used in this study. In view of these differences, conclusions of acute dopaminergic administration in healthy populations cannot be extrapolated to patients with PD. Instead, we encourage specific investigation into the role of dopamine agonists in PD.

Conclusions

Our results from a placebo controlled, double-blind study provide novel evidence that an acute dose of ropinirole selectively reduces proactive inhibition in healthy participants. The results of the HDDM further indicate that ropinirole results in less context-specific adjustment of the boundary separation when stopping is potentially required. These results

may have implications for the potential of this dopamine agonist with high D_3 affinity to induce impulse control disorders in susceptible patients with Parkinson's disease.

Funding

Acknowledgements

Author contributions

All authors contributed in the design of the study. All authors were involved in the drafting and revisions of the manuscript. TF provided the ropinirole and placebo used in the study. VR collected and analysed data. All authors have approved this manuscript.

Figure 1: The Conditional stop-signal task (CSST).

The different trial types on the CSST with their appropriate responses (critical direction is right). All stimuli stay on the screen until the next stimulus appears. The stop signal delay (SSD) changes between one of four values depending on the performance of the previous critical stop trial.

Figure 2: Real and HDDM-predicted reaction times.

Plots show predicted (red) and real (blue) reaction times organised by quantile, for each trial/drug permutation. Reaction times are simulated using the HDDM model with the lowest DIC value.

Figure 3: Drift-diffusion model parameters between critical and non-critical Go trials for participants on ropinirole or placebo.

Posterior probability distributions are plotted for drug (ropinirole), trial type (non-critical) and an interaction between the two. The blue, vertical line represents the no-

effect value. Statistical significance is confirmed if >95% of the distribution lies outside of this line.

Table 1: Behavioural measurements from the Conditional Stop-signal task performed by participants on placebo and ropinirole. Mean values are accompanied by SD in brackets. Reaction times are given in milliseconds.

Table 2: Deviance information criterion values for each model. The Table shows the DIC value for each model tested. A lower DIC value indicates a greater likelihood for that model. a = boundary separation, v = drift rate, n = non-decision time.

References

1. Jahanshahi M, Obeso I, Rothwell JC, Obeso JA. A fronto-striato-subthalamic-pallidal network for goal-directed and habitual inhibition. Nat Rev Neurosci. 2015;16:719–732.

2. Bellgrove MA, Chambers CD, Vance A, Hall N, Karamitsios M, Bradshaw JL. Lateralized deficit of response inhibition in early-onset schizophrenia. Psychol Med. 2006;36:495–505.

3. Garavan H, Hester R. The role of cognitive control in cocaine dependence. Neuropsychol Rev. 2007;17:337–345.

4. Crosbie J, Schachar R. Deficient inhibition as a marker for familial ADHD. Am J Psychiatry. 2001;158:1884–1890.

5. Weintraub D, David AS, Evans AH, Grant JE, Stacy M. Clinical spectrum of impulse control disorders in Parkinson's disease. Mov Disord. 2015;30:121–127.

6. Aron AR. From reactive to proactive and selective control: Developing a richer model for stopping inappropriate responses. Biol Psychiatry. 2011;69:e55–e68.

7. Frank MJ. Dynamic dopamine modulation in the basal ganglia: A neurocomputational account of cognitive deficits in medicated and nonmedicated Parkinsonism. J Cogn Neurosci. 2005;17:51–72.

8. Pattij T, Vanderschuren LJMJ. The neuropharmacology of impulsive behaviour. Trends Pharmacol Sci. 2008;29:192–199.

9. Eagle DM, Wong JCK, Allan ME, Mar AC, Theobald DE, Robbins TW. Contrasting Roles for Dopamine D1 and D2 Receptor Subtypes in the Dorsomedial Striatum but Not the Nucleus Accumbens Core during Behavioral Inhibition in the Stop-Signal Task in Rats. J Neurosci. 2011;31:7349–7356.

10. Ghahremani DG, Lee B, Robertson CL, Tabibnia G, Morgan AT, De Shetler N, et al. Striatal dopamine D□/D□ receptors mediate response inhibition and related activity in frontostriatal neural circuitry in humans. J Neurosci. 2012;32:7316–7324.

11. Hamidovic A, Dlugos A, Skol A, Palmer AA, Wit H de. Evaluation of Genetic Variability in the Dopamine Receptor D2 in Relation to Behavioral Inhibition and Impulsivity/Sensation Seeking: An Exploratory Study With d-Amphetamine in

Healthy Participants. Exp Clin Psychopharmacol. 2009;17:374–383.

12. London ED. Impulsivity, Stimulant Abuse, and Dopamine Receptor Signaling. vol. 76. 1st ed. Elsevier Inc.; 2016.

13. Seeman P. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse. 2015;69:183–189.

14. Weiss HD, Marsh L. Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease. Neurol Clin Pract. 2012;2:267–274.

15. Murphy A, Nestor LJ, McGonigle J, Paterson L, Boyapati V, Ersche KD, et al. Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response during Monetary Reward Anticipation in Drug and Alcohol Dependence. Neuropsychopharmacology. 2017;42:1049–1057.

16. Macdonald HJ, Stinear CM, Ren A, Coxon JP, Kao J, Macdonald L, et al. Dopamine gene profiling to predict impulse control and effects of dopamine agonist ropinirole. J Cogn Neurosci. 2012;10:909–919.

17. Coldwell MC, Boyfield I, Brown T, Hagan JJ, Middlemiss DN. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D(2(long)), D3and D4.4receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1999;127:1696–1702.

18. Perachon S, Schwartz JC, Sokoloff P. Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2and D3receptors. Eur J Pharmacol. 1999;366:293–300.

19. Obeso I, Wilkinson L, Casabona E, Bringas ML, Álvarez M, Álvarez L, et al. Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson's disease. Exp Brain Res. 2011;212:371–384.

20. Obeso I, Wilkinson L, Casabona E, Speekenbrink M, Bringas ML, Álvarez M, et al. The subthalamic nucleus and inhibitory control: Impact of subthalamotomy in Parkinson's disease. Brain. 2014;137:1470–1480.

21. Jahfari S, Stinear CM, Claffey M, Verbruggen F, Aron AR. Responding with restraint: What are the neurocognitive mechanisms? J Cogn Neurosci. 2010;22:1479–1492.

22. Rawji V, Modi S, Latorre A, Rocchi L, Hockey L, Bhatia K, et al. Impaired automatic

but intact volitional inhibition in primary tic disorders. Brain. 2020;143:906–919.

23. Verbruggen F, Chambers CD, Logan GD. Fictitious Inhibitory Differences: How Skewness and Slowing Distort the Estimation of Stopping Latencies. Psychol Sci. 2013;24:352–362.

24. Verbruggen F, Logan GD. Models of response inhibition in the stop-signal and stop-change paradigms. Neurosci Biobehav Rev. 2009;33:647–661.

25. Monte-Silva K, Kuo M-F, Thirugnanasambandam N, Liebetanz D, Paulus W, Nitsche MA. Dose-Dependent Inverted U-Shaped Effect of Dopamine (D2-Like) Receptor Activation on Focal and Nonfocal Plasticity in Humans. J Neurosci. 2009;29:6124–6131.

26. Acton G, Broom C. A dose rising study of the safety and effects on serum prolactin of SK&F 101468, a novel dopamine D2☐receptor agonist. Br J Clin Pharmacol. 1989;28:435–441.

27. Wiecki T V., Sofer I, Frank MJ. HDDM: Hierarchical Bayesian estimation of the Drift-Diffusion Model in Python. Front Neuroinform. 2013;7:1–10.

28. Huang YT, Georgiev D, Foltynie T, Limousin P, Speekenbrink M, Jahanshahi M. Different effects of dopaminergic medication on perceptual decision-making in Parkinson's disease as a function of task difficulty and speed-accuracy instructions. Neuropsychologia. 2015;75:577–587.

29. Roessner V, Albrecht B, Dechent P, Baudewig J, Rothenberger A. Normal response inhibition in boys with Tourette syndrome. Behav Brain Funct. 2008;4:1–6.

30. Robertson CL, Ishibashi K, Mandelkern MA, Brown AK, Ghahremani DG, Sabb F, et al. Striatal D1- and D2-type dopamine receptors are linked to motor response inhibition in human subjects. J Neurosci. 2015;35:5990–5997.

31. Lorenz RC, Gleich T, Buchert R, Schlagenhauf F, Kühn S, Gallinat J. Interactions between glutamate, dopamine, and the neuronal signature of response inhibition in the human striatum. Hum Brain Mapp. 2015;36:4031–4040.

32. Logemann HNA, Böcker KBE, Deschamps PKH, van Harten PN, Koning J, Kemner C, et al. Haloperidol 2 mg impairs inhibition but not visuospatial attention. Psychopharmacology (Berl). 2017;234:235–244.

33. Nandam LS, Hester R, Wagner J, Dean AJ, Messer C, Honeysett A, et al. Dopamine D2 receptor modulation of human response inhibition and error awareness. J Cogn Neurosci. 2013;25:649–656.

34. Nandam LS, Hester R, Wagner J, Cummins TDR, Garner K, Dean AJ, et al. Methylphenidate but not atomoxetine or citalopram modulates inhibitory control and response time variability. Biol Psychiatry. 2011;69:902–904.

35. Farrell SM, Tunbridge EM, Braeutigam S, Harrison PJ. COMT Val158met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition. Biol Psychiatry. 2012;71:538–544.

36. Congdon E, Constable RT, Lesch KP, Canli T. Influence of SLC6A3 and COMT variation on neural activation during response inhibition. Biol Psychol. 2009;81:144–152.

37. Kraemmer J, Smith K, Weintraub D, Guillemot V, Nalls MA, Cormier-Dequaire F, et al. Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2016;87:1106–1111.

38. Beu ND, Burns NR, Baetu I. Polymorphisms in dopaminergic genes predict proactive processes of response inhibition. Eur J Neurosci. 2019;49:1127–1148.

39. Beste C, Adelhöfer N, Gohil K, Passow S, Roessner V, Li SC. Dopamine modulates the efficiency of sensory evidence accumulation during perceptual decision making. Int J Neuropsychopharmacol. 2018;21:649–655.

40. Rincón-Pérez I, Echeverry-Alzate V, Sánchez-Carmona AJ, Bühler KM, Hinojosa JA, López-Moreno JA, et al. The influence of dopaminergic polymorphisms on selective stopping. Behav Brain Res. 2020;381:112441.

41. Georgiev D, Rocchi L, Tocco P, Speekenbrink M, Rothwell JC, Jahanshahi M. Continuous Theta Burst Stimulation Over the Dorsolateral Prefrontal Cortex and the Pre-SMA Alter Drift Rate and Response Thresholds Respectively During Perceptual Decision-Making. Brain Stimul. 2016;9:601–608.

42. Winkel J, van Maanen L, Ratcliff R, Van der Schaaf ME, Van Schouwenburg MR, Cools R, et al. Bromocriptine does not alter speed-accuracy tradeoff. Front Neurosci. 2012;6:1–8.

43. Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet.

2000;39:243–254.